Romosozumab (Evenity) for Postmenopausal Osteoporosis

Date: June 3, 2019 Issue #:  1573Summary:  The FDA has approved romosozumab-aqqg (Evenity– Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. R omosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide(Tymlos) and teriparatide(Forteo) were approved earlier. Other drugs used for treatment of postmenopausal osteoporosis, such as bisphosphonates, inhibit bone resorption and decrease bone turnover.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research